Stephen Kim is an Ophthalmology physician. ClinicalTrials.gov lists 8 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 The Vanderbilt Clinic
Nashville, TN 372320001
Telephone
615-322-3000Provider last certified this registry record 26 Dec 2025.
Clinical trials
- INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study
Sponsor: Stephen J. Kim, MD
- The Effects of a Music Therapist Designed Listening Program on Intraoperative Vitrectomy
Sponsor: Vanderbilt University Medical Center
- The Role of Prostaglandins in the Progression of Diabetic Retinopathy
Sponsor: Vanderbilt University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20251 payment
- ANI Pharmaceuticals, Inc.Program year20251 payment
- Alimera Sciences, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
44.4%Vascular Endothelial Growth Factor Inhibitor40.8%Bevacizumab54%Aflibercept46%Part B, office-administered≥81 patientsCalcineurin inhibitor2.4%Restasis59%Cyclosporine41%Part D<11 patients+ 2 more classes in this area
Sensory organs
38.4%Prostaglandin Analog15.2%Latanoprost96%Travoprost4%Part D<11 patientsCorticosteroid11.2%Prednisolone Acetate58%Fluorometholone42%Part D≥58 patients+ 4 more classes in this area
Metabolism & gastrointestinal
8.5%Corticosteroid7.8%Prednisone100%Part D≥42 patientsAnticholinergic0.7%Atropine Sulfate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2020–2024 per NIH RePORTER. The latest:
- Ocular Inflammatory Mediators in the Pathophysiology of Diabetic Retinopathy
Vanderbilt University Medical Center
FY2024$432,500R01EY031315 - Ocular Inflammatory Mediators in the Pathophysiology of Diabetic Retinopathy
Vanderbilt University Medical Center
FY2023$432,500R01EY031315 - Ocular Inflammatory Mediators in the Pathophysiology of Diabetic Retinopathy
Vanderbilt University Medical Center
FY2022$419,525R01EY031315
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”